Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36. Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Watson C Value Health. 2015 Nov; 18(7):A713. Epub 2015 Oct 20. PMID: 26533994. Abstract CommentRecommendBookmarkWatch